000			nab a22 7a 4500
999			_c16978 _d16978
003			PC16978
005			20220824112425.0
008			220824b xxu||||| |||| 00| 0 eng d
040			_cH12O
041			_aspa
100			_9433 _aSepúlveda Sánchez, Juan Manuel _eOncología Médica
245	0	0	_aEl receptor del factor de crecimiento epidérmico (EGFR) en el glioblastoma: mecanismo de tumorigénesis y papel como diana terapéutica. _h[revisión]
260			_bRevista de neurología, _c2015
300			_a61(2):85-93.
500			_aFormato Vancouver: Zahonero C, Sepúlveda JM, Sánchez Gómez P. El receptor del factor de crecimiento epidérmico (EGFR) en el glioblastoma: mecanismo de tumorigénesis y papel como diana terapéutica. Rev Neurol. 2015 Jul 16;61(2):85-93.
501			_a PMID: 26156444
504			_aContiene 81 referencias
520			_aA glioblastoma is a primary brain tumour that is very aggressive and resistant to conventional treatment with chemo- or radiotherapy. Given that epidermic growth factor receptor (EGFR) is altered in 50% of glioblastomas, it is currently one of the most promising therapeutic targets in this kind of tumour. Yet, inhibitors of the kinase activity of EGFR have yielded poor results in clinical trials with patients with glioblastomas. In this review we analyse the function of EGFR in glioblastomas and outline the therapeutic approaches aimed against this receptor in this kind of tumour. This sort of analysis could be a starting point for improving the design of future therapies for glioblastomas, based on inhibiting the EGFR function.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16978.pdf _ySolicitar documento
942			_2ddc _cREV _n0